Cue Biopharma CUE
NASDAQ CUE
$28.03 -2.47 (-8.10%)
As of: Sep 10, 2026 · 3:59 PM EDT

Cue Biopharma (CUE) Non Operating Interest Expenses (2022)

Cue Biopharma's (CUE) quarterly Non Operating Interest Expenses came in at $124000.0 in Q3 2022, down 39.81% quarter-over-quarter from $206000.0 in Q2 2022.

Analysis

Cue Biopharma (CUE) Non Operating Interest Expenses (2022) Analysis & Trends

Cue Biopharma has disclosed Non Operating Interest Expenses across 1 years of filings, most recently posting $124000.0 for Q3 2022.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -1.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn -
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Cue Biopharma 179.95 Mn 162.53 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 124,000.00
Jun 30, 2022 206,000.00
Mar 31, 2022 25,000.00